Status:
COMPLETED
A Study of DCC-2618 (Ripretinib) In Patients With With Advanced Gastrointestinal Stromal Tumors (GIST)
Lead Sponsor:
Zai Lab (Shanghai) Co., Ltd.
Conditions:
Gastrointestinal Stromal Tumors
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
The primary objective of this trial is to evaluate the progress free survival (PFS) of DCC-2618 in patients with advanced gastrointestinal stromal tumors who have progressed with prior anticancer ther...
Detailed Description
The primary objective of this trial is to evaluate the progress free survival (PFS) of DCC-2618 in patients with advanced gastrointestinal stromal tumors who have progressed with prior anticancer ther...
Eligibility Criteria
Inclusion
- Male or female patients ≥18 years of age.
- Patients with advanced gastrointestinal stromal tumors.
- Subjects who have progressed or documented intolerance after previous treatments.
- Sign informed consent, understand the Protocol and could follow the Protocol.
- The subject had at least one measurable lesion.
- Adequate organ function and bone marrow reserve
Exclusion
- Treatment with anticancer therapy, including investigational therapy, or investigational procedures within 14 days or 5 x the half-life (whichever is longer) prior to the first dose of investigational drug.
- Prior treatment with DCC-2618.
- Previously or currently has an additional malignancy that is progressing or required active treatment, which may interfere with the safety or efficacy evaluation of DCC-2618.
- Patient has known active central nervous system metastases.
- New York Heart Association class II - IV heart disease, active ischemia or any other uncontrolled cardiac condition.
- Arterial thrombotic or embolic events within 6 months before the first dose of investigational drug.
- Venous thrombotic events within 3 months before the first dose of investigational drug.
- 12-lead electrocardiogram (ECG) demonstrating QT interval corrected by Fridericia's formula \>450 ms in males or \>470 ms in females at screening or history of long QT interval syndrome.
- Left ventricular ejection fraction (LVEF) \<50% at screening.
- Use of known substrates or inhibitors of breast cancer resistance protein (BCRP) transporters within 14 days or 5 x the half-life (whichever is longer) prior to the first dose of investigational drug.
- Major surgeries within 4 weeks of the first dose of investigational drug.
- Any other clinically significant comorbidities, which in the judgment of the investigator, could compromise compliance with the protocol, interfere with interpretation of the study results, or predispose the patient to safety risks.
- Active viral infections.
- If female, the patient is pregnant or lactating, or plans to become pregnant during the study treatment period.
- Known allergy or hypersensitivity to any component of the investigational drug.
- Gastrointestinal abnormalities.
- Any active hemorrhages, excluding hemorrhoids or gum bleeding.
Key Trial Info
Start Date :
April 23 2020
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
August 23 2022
Estimated Enrollment :
39 Patients enrolled
Trial Details
Trial ID
NCT04282980
Start Date
April 23 2020
End Date
August 23 2022
Last Update
March 3 2025
Active Locations (9)
Enter a location and click search to find clinical trials sorted by distance.
1
Beijing Cancer Hospital
Beijing, Beijing Municipality, China
2
Chinese People's Liberation Army General Hospital
Beijing, Beijing Municipality, China
3
Union Medical College Hospital, Chongqing Medical University
Chongqing, Chongqing Municipality, China
4
Union Medical College Hospital, Fujian Medical University
Fuzhou, Fujian, China